Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||MDM2 positive|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MDM2 positive||triple-receptor negative breast cancer||sensitive||YF438||Preclinical||Actionable||In a preclinical study, YF438 treatment inhibited H3 and H4 acetylation, promoted Mdm2 degradation, led to growth inhibition and increased apoptosis in triple-negative breast cancer cell lines in culture, and reduced tumor growth and metastasis, extended overall survival in an orthotopic autograft model (PMID: 33985974).||33985974|
|MDM2 positive||triple-receptor negative breast cancer||sensitive||Doxorubicin + YF438||Preclinical||Actionable||In a preclinical study, YF438 and Adriamycin (doxorubicin) combination treatment synergistically inhibited tumor growth compared to either drug alone in an orthotopic autograft model of triple-negative breast cancer (PMID: 33985974).||33985974|